Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Affimed to Present at the Cowen and Company 36th Annual Health Care Conference

AFMD

HEIDELBERG, Germany, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Florian Fischer, CFO, will present at the Cowen and Company 36th Annual Health Care Conference on Monday, March 7, 2016 at 3:20 p.m. (ET) in Boston.

To access a simultaneous webcast of Dr. Fischers' presentation at the Conference online, log on to http://wsw.com/webcast/cowen30/afmd or go to the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available from Affimed's website for 30 days following the conference. Dr. Fischers' presentation will be available for download in PDF format immediately following the conference presentation in the "Events" section of the Media page of Affimed's website at http://www.affimed.com/events.php.

About Affimed N.V.

Affimed (Nasdaq:AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit www.affimed.com.

CONTACT: IR Contact:
         Caroline Stewart, Head IR
         Phone: +1 347394 6793
         E-Mail: IR@affimed.com or c.stewart@affimed.com
         
         Media Contact:
         Anca Alexandru, Head of Communications
         Phone: +49 6221 64793341
         E-Mail: a.alexandru@affimed.com

Affimed Therapeutics logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today